Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Table 2

Immunological response.

	Docetaxel + placebo	Docetaxel + PPV
Prevaccination
	24	26
2 peptide-specific IgGs	1	3
3 peptide-specific IgGs	1	4
4 peptide-specific IgGs	22	19
Postvaccination
	22	25
Humoral responder	1	14
Cellular responder	Not examined	14
Positive skin reaction	4	13